![David M. Byers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Donald F. Weaver | M | - |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada.
Dalhousie University
| 18 years |
Christopher R. McMaster | M | - |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada.
Dalhousie University
| 18 years |
Deep Saini | M | - |
Dalhousie University
| - |
Scott Brison | M | 57 |
Dalhousie University
| - |
Christopher J. Barden | M | - |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
Thomas Traves | M | 75 |
Dalhousie University
| 29 years |
James Lawley | M | 65 |
Dalhousie University
| - |
John Risley | M | 76 |
Dalhousie University
| - |
Rakesh Jetly | M | 57 |
Dalhousie University
| - |
Melanie Kelly | F | - |
Dalhousie University
| 33 years |
Kim Brewer | F | - |
Dalhousie University
| - |
Sherry Porter | F | 68 |
Dalhousie University
| - |
Cheryl Fraser | F | - |
Dalhousie University
| - |
Michael Kirby | M | 81 |
Dalhousie University
| - |
Robert Radchuck | M | - |
Dalhousie University
| - |
Marlene Haffner | M | 83 |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
Fan Wu | M | - |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
Marcia Taylor | M | - |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | 13 years |
Richard Florizone | M | - |
Dalhousie University
| - |
C. Shepherd | M | - |
Dalhousie University
| - |
Lidija Marusic | M | - |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
Tanya Shaw Weeks | F | - |
Dalhousie University
| - |
Graham Judson Day | M | 91 |
Dalhousie University
| - |
Sultan Darvesh | M | - |
Dalhousie University
| - |
Marlon Lewis | M | - |
Dalhousie University
| - |
Tong Jun Lin | M | 62 |
Dalhousie University
| - |
Robert Hanf | M | 61 |
Dalhousie University
| - |
Sarah MacDonald | F | - |
Dalhousie University
| - |
William Black | M | - |
Dalhousie University
| - |
Margaret Cunningham | M | - |
Dalhousie University
| 14 years |
Michael Gross | M | - |
Dalhousie University
| - |
Robert Richardson | M | 62 |
Dalhousie University
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kevin V. Sullivan | M | 49 |
DeNovaMed, Inc.
![]() DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 33 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David M. Byers
- Personal Network